Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Acorda Therapeutics (ACORQ) has shared an announcement.
Acorda Therapeutics, Inc. has finalized an asset sale to Merz Pharmaceuticals for $185 million, after filing for Chapter 11 bankruptcy. The company’s equity will be canceled, with no distributions to equity holders, as a Liquidation Plan takes effect. A Liquidating Trustee will manage the sale proceeds and handle the company’s dissolution, representing a significant shift in the company’s trajectory and a cautionary tale for investors in similar situations.
Learn more about ACORQ stock on TipRanks’ Stock Analysis page.